News 

- Growth in performance indicators in absolute terms:

   o Sale: € 1.57 billion, up € 113 million (+7.8%), reflecting the incorporation of LISI MEDICAL Remmele (€ 45 million for 7 months) in particular;

   o Organic growth: +4.6%, driven by the three divisions;

   o EBIT up € 11 million (+7.5%), with operating margin in line with the strategic target of 10.0%;

   o Positive Free Cash-Flow*, up almost € 34 million at € 74 million.

- Financial strength maintained:

   o Net debt / EBITDA ratio maintained below than 1, despite substantial capital expenditure programs (€ 120 million) and financial investments (€ 94 million) in 2016.

- Net earnings per share up: +30.0%;

- Proposed dividend: € 0.45 per share;

- 2017 targets: to continue and consolidate performance over the long-term.

Outlook

With this in mind the LISI Group is aiming in 2017 a growth in its operating results and a Free Cash Flow that continues to be positive.